WHWK
Whitehawk Therapeutics Inc
$
2.070
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
2.120
Open
2.100
VWAP
2.07
Vol
266.90K
Mkt Cap
97.56M
Low
2.010
Amount
552.69K
EV/EBITDA(TTM)
--
Total Shares
47.13M
EV
-65.04M
EV/OCF(TTM)
--
P/S(TTM)
7.39
Whitehawk Therapeutics, Inc., formerly Aadi Bioscience, Inc., is a preclinical stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Its advanced three-asset antibody drug conjugate (ADC) portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. Its assets include HWK-007, HWK-016 and HWK-206. HWK-007 represents a differentiated opportunity to potentially be among the first next-wave ADCs in clinical development for high PTK7-expressing cancers. HWK-016 is the first ADC that targets the membrane-bound portion of MUC16, a glycoprotein often overexpressed in cancers of female origin. HWK-016 is being evaluated in IND-enabling studies. HWK-206 is designed to address the neuronal target, SEZ6, which is often overexpressed in cancers of neuroendocrine origin.
Show More
Valuation Metrics
The current forward P/E ratio for Whitehawk Therapeutics Inc (WHWK.O) is -1.39, compared to its 5-year average forward P/E of -1.98. For a more detailed relative valuation and DCF analysis to assess Whitehawk Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-1.98
Current PE
-1.39
Overvalued PE
-1.22
Undervalued PE
-2.74
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Fair
5Y Average PS
2.39
Current PS
2.10
Overvalued PS
3.08
Undervalued PS
1.71
Financials
Annual
Quarterly
FY2025Q3
YoY :
-100.00%
0.00
Total Revenue
FY2025Q3
YoY :
+81.40%
-19.55M
Operating Profit
FY2025Q3
YoY :
+41.45%
-17.75M
Net Income after Tax
FY2025Q3
YoY :
-43.48%
-0.26
EPS - Diluted
FY2025Q3
YoY :
-3.13%
-15.38M
Free Cash Flow
FY2025Q3
YoY :
+0.57%
89.36
Gross Profit Margin - %
FY2025Q3
YoY :
+196.50%
-667.34
FCF Margin - %
FY2025Q3
YoY :
-121.36%
37.16
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 230.74% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
1.5M
Volume
1
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
3
7.6M
Volume
Months
0-12
1
2.3M
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
WHWK News & Events
Events Timeline
2025-11-06 (ET)
2025-11-06
08:07:59
Whitehawk Therapeutics Announces Q3 Earnings Per Share of 26 Cents, Compared to 46 Cents Last Year
2025-10-16 (ET)
2025-10-16
08:32:24
Tempus AI partners with Whitehawk Therapeutics to enhance cancer research
2025-03-31 (ET)
2025-03-31
17:33:15
Whitehawk Therapeutics files to sell 41.67M shares of common stock for holders
Sign Up For More Events
Sign Up For More Events
News
9.5
11-06PRnewswirePinnedWhitehawk Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
9.0
10-24NewsfilterWhitehawk Therapeutics Unveils Real-World Study Supporting PTK7 as a Widely Expressed and Clinically Significant Target in Solid Tumors at AACR-NCI-EORTC
7.5
10-16SeekingAlphaTempus Collaborates with Whitehawk Therapeutics to Enhance Cancer Research
Sign Up For More News
People Also Watch
AVGO
Broadcom Inc
349.430
USD
-1.73%
XOM
Exxon Mobil Corp
117.220
USD
+2.38%
ORCL
Oracle Corp
239.260
USD
-1.86%
MSFT
Microsoft Corp
496.820
USD
-0.06%
AAPL
Apple Inc
268.470
USD
-0.48%
TSLA
Tesla Inc
429.520
USD
-3.68%
WMT
Walmart Inc
102.590
USD
+0.89%
NVDA
NVIDIA Corp
188.150
USD
+0.04%
AMZN
Amazon.com Inc
244.410
USD
+0.56%
META
Meta Platforms Inc
621.710
USD
+0.45%
FAQ
What is Whitehawk Therapeutics Inc (WHWK) stock price today?
The current price of WHWK is 2.07 USD — it has decreased -1.43 % in the last trading day.
What is Whitehawk Therapeutics Inc (WHWK)'s business?
What is the price predicton of WHWK Stock?
What is Whitehawk Therapeutics Inc (WHWK)'s revenue for the last quarter?
What is Whitehawk Therapeutics Inc (WHWK)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Whitehawk Therapeutics Inc (WHWK)'s fundamentals?
How many employees does Whitehawk Therapeutics Inc (WHWK). have?